Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Recurrent Oligometastatic Prostate Cancer
NCT04011410Phase 2Completed
- Start
- Dec 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxychloroquine in prostate cancer (PCa). Primary endpoint: Participants With Greater Than or Equal to 50% Induction in Serum PAR4 Levels at 90 days. Started Dec 2019; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04011410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04011410.